BƯỚC ĐẦU ĐÁNH GIÁ HIỆU QUẢ VÀ ĐỘ AN TOÀN CỦA EMICIZUMAB TRONG ĐIỀU TRỊ DỰ PHÒNG Ở BỆNH NHI HEMOPHILIA A TẠI BỆNH VIỆN TRUYỀN MÁU HUYẾT HỌC – BÁO CÁO LOẠT 5 CA BỆNH
Objective: To evaluate the efficacy of emicizumab and identify treatment-related adverse events in pediatric patients with hemophilia A.Subjects and methods: A retrospective case-series study was conducted in 5 male pediatric patients diagnosed with hemophilia A (HA) and treated with emicizumab at the Blood Transfusion and Hematology Hospital between February 2022 and February 2024. Treatment efficacy was assessed using the annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), target joint status, and the Hemophilia Joint Health Score (HJHS). Safety was evaluated through the monitoring of adverse events.Results: Following emicizumab treatment, ABR decreased markedly in all patients, AJBR decreased in all four patients with joint bleeding before treatment, and the post-treatment HJHS was 0 in all patients. Four of the five patients had no adverse events; one patient developed injection-site swelling and itching with fever.Conclusion: Preliminary findings suggest that emicizumab is an effective and safe prophylactic therapy for pediatric patients with HA, reducing bleeding episodes and stabilizing joint status with few adverse effects.
Authors
- Chí Dũng Phù
- Văn Tân Ngô
- Thảo Nguyên Vương
- Thị Hương Giang Nguyễn
Publication Details
- Journal
- Journal of Clinical Medicine Bach Mai Hospital
- Published
- 2026-11-21
- DOI
- https://doi.org/10.52322/jocmbmh.156.0315
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00